BioMarin signs deal worth $475 M with Korea's GC Biopharma and Hanmi Pharm for potential treatment of Fabry Disease ...

A final day on neurotechnology, AI drug discovery that must prove its value and a live brain-computer interface demonstration ...

Fund has announced a total investment of approximately JPY 1.06 billion ($6.8 million) in nine R&D projects for the ...

Waters Corporation has announced AI-Powered Peak Integration, the next step in its strategy to build intelligent AI, machine ...

Speaking to BioSpectrum Asia at BIOPLUS-INTERPHEX KOREA 2026, Dr Sally Temple highlights how advances in RPE transplantation, ...

PeptiDream Inc., a public biopharmaceutical company based in Kawasaki, Japan, focused on the discovery and development of ...

Under the agreement, Astellas receives an exclusive option which, on exercise, will grant Astellas a worldwide license to ...

M42 and the American University in Dubai (AUD) have signed a Memorandum of Understanding (MoU) to expand practical learning ...

If Day 1 of BIX 2026 asked what makes a Korean asset partnerable, Day 2 asked what happens once someone wants it. Thursday's ...

Singapore’s HSA approves MSD’s CAPVAXIVE for prevention of invasive pneumococcal disease and pneumococcal pneumonia in adults ...

SG Austria/Austrianova announces a peer-reviewed perspective exploring encapsulated cells for sustained delivery of the ageing-associated protein Klotho.

Jiahui International Hospital has launched Jiahui International Cell Therapy Centre (JICC), building on landmark CAR-T cases ...